Hemodynamic, renal, and endocrine effects of 4-h infusions of human atrial natriuretic peptide in normal volunteers.


Autoria(s): Bidiville J.; Waeber G.; Porchet M.; Nussberger J.; Biollaz J.; Gomez H.; Callahan L.; Waeber B.; Brunner H.R.
Data(s)

1988

Resumo

A synthetic human atrial natriuretic peptide of 26 aminoacids [human (3-28)ANP or hANP] was infused into normal male volunteers. Six subjects were infused for 4 h at 1-wk intervals with either hANP at the rate of 0.5 or 1.0 microgram/min or its vehicle in a single-blind randomized order. Human (3-28)ANP at the dose of 0.5 microgram/min raised immunoreactive plasma ANP levels from 104 +/- 17 to 221 +/- 24 pg/ml (mean +/- SEM), but it induced no significant change in blood pressure, heart rate, effective renal plasma flow, glomerular filtration rate, or renal electrolyte excretion. At the rate of 1.0 microgram/min, human (3-28)ANP increased immunoreactive plasma ANP levels from 89 +/- 12 to 454 +/- 30 pg/ml. It reduced effective renal plasma flow from 523 +/- 40 to 453 +/- 38 ml/min (P less than 0.05 vs. vehicle), but left glomerular filtration rate unchanged. Natriuresis rose from 207 +/- 52 to 501 +/- 69 mumol/min (P less than 0.05 vs. vehicle) and urinary magnesium excretion from 3.6 +/- 0.5 to 5.6 +/- 0.5 mumol/min (P less than 0.01 vs. vehicle). The excretion rate of the other electrolytes, blood pressure, and heart rate were not significantly modified. At both doses, human (3-28)ANP tended to suppress the activity of the renin-angiotensin-aldosterone system. In 3 additional volunteers, the skin blood flow response to human (3-28)ANP, infused for 4 h at the rate of 1.0 microgram/min, was studied by means of a laser-doppler flowmeter. The skin blood flow rose during the first 2 h of peptide administration, then fell progressively to values below baseline. After the infusion was discontinued, it remained depressed for more than 2 h. Thus, in normal volunteers, human (3-28)ANP at the dose of 1.0 microgram/min produced results similar to those obtained previously with rat (3-28)ANP. It enhanced natriuresis without changing the glomerular filtration rate while effective renal plasma flow fell. It also induced a transient vasodilation of the skin vascular bed.

Identificador

http://serval.unil.ch/?id=serval:BIB_52EB2E10411B

isbn:0767-3981

pmid:2976727

doi:10.1111/j.1472-8206.1988.tb01007.x

isiid:A1988R099300005

Idioma(s)

en

Fonte

Fundamental & clinical pharmacology, vol. 2, no. 5, pp. 413-29

Palavras-Chave #Adult; Atrial Natriuretic Factor; Blood Pressure; Clinical Trials as Topic; Endocrine Glands; Heart Rate; Hemodynamics; Humans; Infusions, Intravenous; Kidney; Male; Peptide Fragments; Random Allocation; Regional Blood Flow; Renal Circulation; Skin
Tipo

info:eu-repo/semantics/article

article